These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. mRNA Cancer Vaccines-Messages that Prevail. Grunwitz C; Kranz LM Curr Top Microbiol Immunol; 2017; 405():145-164. PubMed ID: 28401358 [TBL] [Abstract][Full Text] [Related]
13. Innate immunity and vaccines. Platt A; Wetzler L Curr Top Med Chem; 2013; 13(20):2597-608. PubMed ID: 24066890 [TBL] [Abstract][Full Text] [Related]
14. Systems integration of innate and adaptive immunity. Zak DE; Aderem A Vaccine; 2015 Sep; 33(40):5241-8. PubMed ID: 26102534 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic mRNA delivery to leukocytes. Granot-Matok Y; Kon E; Dammes N; Mechtinger G; Peer D J Control Release; 2019 Jul; 305():165-175. PubMed ID: 31121277 [TBL] [Abstract][Full Text] [Related]
16. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Leroux-Roels G Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254 [TBL] [Abstract][Full Text] [Related]
17. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Alter G; Sekaly RP Vaccine; 2015 Jun; 33 Suppl 2():B55-9. PubMed ID: 26022570 [TBL] [Abstract][Full Text] [Related]
18. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884 [TBL] [Abstract][Full Text] [Related]
19. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Maruggi G; Zhang C; Li J; Ulmer JB; Yu D Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823 [TBL] [Abstract][Full Text] [Related]
20. Measuring the Adjuvant Activity of RNA Vaccines. Pardi N; Weissman D Methods Mol Biol; 2017; 1499():143-153. PubMed ID: 27987147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]